Lavipharm SA

As of December 31, 2024, Lavipharm SA carries a market capitalization of 134.11M, placing it among publicly traded companies globally. Its enterprise value stands at 162.33M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Lavipharm SA's next confirmed earnings release is scheduled for March 3, 2027.

As of December 31, 2024, Lavipharm SA has 168.69M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Lavipharm SA maintains a current ratio of 1.15, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 22, 2026, Lavipharm SA's stock has gained approximately 83.75% over the past 52 weeks. The 50-day moving average sits at 1.57, while the 200-day moving average is 1.44.

As of December 31, 2024, Lavipharm SA holds 5.59M in cash and equivalents against 33.82M in total debt, resulting in a net debt position of 17.15M. Total book value stands at 52.98M, with working capital of 5.88M providing operational flexibility.

Lavipharm SA's most recent stock split took place on November 28, 2022 with a 148:159 split ratio.